Premium
Association of dopamine D2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: A systematic review and meta‐analysis
Author(s) -
Ma Lingyue,
Xiang Qian,
Zhou Shuang,
Tan Yunlong,
Zhang Xiaodan,
Yang Ting,
Xie Qiufen,
Mu Guangyan,
Zhao Xia,
Zhou Ying,
Li Suxia,
Cui Yimin
Publication year - 2019
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12843
Subject(s) - risperidone , meta analysis , dopamine receptor d2 , dopamine receptor , medicine , dopamine , pharmacogenetics , genetics , polymorphism (computer science) , association (psychology) , genetic association , gene , pharmacology , bioinformatics , oncology , biology , psychiatry , psychology , single nucleotide polymorphism , genotype , schizophrenia (object oriented programming) , psychotherapist
What is known and objective Dopamine D 2 receptor (DRD2) polymorphisms are inconsistently associated with elevated prolactin levels related to risperidone treatment. The aim of this systematic review and meta‐analysis was to investigate whether DRD2 polymorphisms could modulate prolactin levels in patients treated with risperidone.Methods Three electronic databases (PubMed, EMBASE and the Cochrane Library) were searched for studies investigating the effect of DRD2 polymorphisms on prolactin levels in patients treated with risperidone until May 2018. Summary standard mean differences (SMDs) and 95% confidence intervals (CIs) were calculated with Hedges' g tests for effect estimates using random effects models. The heterogeneity, sensitivity, univariable meta‐regression, subgroup analyses and publication biases were calculated.Results and discussion After initially identifying 886 studies, 772 patients from eight studies were included. Summary SMDs indicated that compared with A1 non‐carriers, Taq1A A1 carriers did not have different risperidone‐related prolactin levels (SMD: 0.13; 95% CI: −0.18 to 0.43; P = 0.423) among patients with schizophrenia (SCZ; SMD: 0.07; 95% CI: −0.14 to 0.29; P = 0.505) or among those without SCZ (SMD: 0.16; 95% CI: −0.39 to 0.71; P = 0.562). There was no significant difference between Del carriers and Del non‐carriers with regard to risperidone‐related prolactin levels (SMD: −0.00; 95% CI: −0.59 to 0.58; P = 0.996). In an Asian subgroup analysis, we also noted that compared with Taq1A A1A2 carriers, Taq1A A1A1 carriers had lower prolactin levels (SMD: −0.34; 95% CI: −0.66 to −0.02; P = 0.040). However, there was no significant difference in prolactin levels between A1A1 carriers and A2A2 carriers (SMD: −0.27; 95% CI: −0.60 to 0.05; P = 0.098), or between A2 carriers and A2 non‐carriers (SMD: 0.29; 95% CI: −0.01 to 0.59; P = 0.059). Based on univariable meta‐regression analyses, the effects of publication year, study design, ethnicity, comparison groups and study quality could bias the identified association of DRD2 Taq1A with risperidone‐related prolactin levels.What is new and conclusion The findings of this study suggest that there is no significant difference between Taq1A A1 carriers and non‐A1 carriers with regard to risperidone‐related prolactin levels. As there were few A1 homozygotes, large prospective studies with robust designs are still needed to investigate whether A1A1 could affect risperidone‐related prolactin levels in the Asian population.